Clinical Trials

Inclusion Criteria: 

• Age ≥18 years or at "full age" as required by local regulation. 
• Evidence of chronic kidney disease at risk of kidney disease progression defined by at least 3 months before and at the time of Screening Visit. 
• CKD-EPI eGFR ≥20 to <45 mL/min/1.73m² or - CKD-EPI eGFR ≥45 to <90 mL/min/1.73m² with urinary albumin:creatinine ratio ≥200 mg/g (or protein:creatinine ratio ≥300 mg/g).
• Clinically appropriate doses of single agent RAS-inhibition with either ACEi or ARB unless such treatment is either not tolerated or not indicated. 
• Neither requires an SGLT-2 or SGLT-1/2 inhibitor, nor that such treatment is inappropriate.

Exclusion Criteria: 

• Currently receiving SGLT-2 or SGLT-1/2 inhibitor.
• Diabetes mellitus type 2 and prior atherosclerotic cardiovascular disease with an eGFR >60 mL/min/1.73m².
• Receiving dual RAS inhibition (two of ACEi, ARB, DRI).
• Any immunosuppression therapy in last 3 months (except prednisolone ≤10 mg or equivalent); or anyone currently on >10 mg prednisolone (or equivalent).
• Maintenance dialysis, functioning kidney transplant, or scheduled living donor transplant; - Polycystic kidney disease; - Previous or scheduled bariatric surgery. 
• Ketoacidosis in the past 5 years.
• Symptomatic hypotension, or systolic blood pressure <90 or >180 mmHg.
• ALT or AST >3x ULN. 
• Hypersensitivity to empagliflozin or other SGLT-2 inhibitor. 
• Known to be poorly compliant with clinic visits or prescribed medication.